The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults

McLeod C., M. Dymock, K.L. Flanagan, M. Plebanski, H. Marshall, M.J. Estcourt, M.C. Tjiam, C.C. Blyth, K. Subbarao, F.L. Mordant, K. Wilson, S. Nicholson, T. Karapanagiotidis, S.N. Faust, U. Wadia, R.B. Thornton, S. Tansil, C. Tedja, Z. Ellis, P.C.M. Williams, A. McKenzie, J.A. Marsh, C. McCallum, T.L. Snelling, P. Richmond

Open source

DOI
10.1016/j.vaccine.2026.128970
Published
2026-08
Container
Vaccine
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.vaccine.2026.128970,
  title = {The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults},
  author = {McLeod C. and M. Dymock and K.L. Flanagan and M. Plebanski and H. Marshall and M.J. Estcourt and M.C. Tjiam and C.C. Blyth and K. Subbarao and F.L. Mordant and K. Wilson and S. Nicholson and T. Karapanagiotidis and S.N. Faust and U. Wadia and R.B. Thornton and S. Tansil and C. Tedja and Z. Ellis and P.C.M. Williams and A. McKenzie and J.A. Marsh and C. McCallum and T.L. Snelling and P. Richmond},
  year = {2026},
  journal = {Vaccine},
  doi = {10.1016/j.vaccine.2026.128970},
  url = {https://doi.org/10.1016/j.vaccine.2026.128970}
}

RIS

TY  - JOUR
TI  - The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults
AU  - McLeod C.
AU  - M. Dymock
AU  - K.L. Flanagan
AU  - M. Plebanski
AU  - H. Marshall
AU  - M.J. Estcourt
AU  - M.C. Tjiam
AU  - C.C. Blyth
AU  - K. Subbarao
AU  - F.L. Mordant
AU  - K. Wilson
AU  - S. Nicholson
AU  - T. Karapanagiotidis
AU  - S.N. Faust
AU  - U. Wadia
AU  - R.B. Thornton
AU  - S. Tansil
AU  - C. Tedja
AU  - Z. Ellis
AU  - P.C.M. Williams
AU  - A. McKenzie
AU  - J.A. Marsh
AU  - C. McCallum
AU  - T.L. Snelling
AU  - P. Richmond
PY  - 2026
JO  - Vaccine
DO  - 10.1016/j.vaccine.2026.128970
UR  - https://doi.org/10.1016/j.vaccine.2026.128970
ER  - 

APA

C., M., Dymock, M., Flanagan, K., Plebanski, M., Marshall, H., Estcourt, M., Tjiam, M., Blyth, C., Subbarao, K., Mordant, F., Wilson, K., Nicholson, S., Karapanagiotidis, T., Faust, S., Wadia, U., Thornton, R., Tansil, S., Tedja, C., Ellis, Z., Williams, P., McKenzie, A., Marsh, J., McCallum, C., Snelling, T., & Richmond, P. (2026). The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128970

Source records